TY 2020 Form 990 Schedule O

Instrumentl eFile RenderObject ID: 202210389349300206 - Rendered 2024-05-05 TIN: 13-1837442

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2020

Open to Public
Inspection

Name of the organization

CANCER RESEARCH INSTITUTE

Employer identification number

13-1837442

Return Reference	Explanation
PART III - STATEMENT OF PROGRAM ACCOMPLISHMENTS, LINE 4D	CLINIC AND LABORATORY INTEGRATION PROGRAM: THE CRI CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP) SUPPORTS QUALIFIED SCIENTISTS WHO ARE WORKING TO EXPLORE CLINICALLY RELEVANT QUESTIONS AIMED AT IMPROVING THE EFFECTIVENESS OF CANCER IMMUNOTHERAPIES. THE PROGRAM FUNDS BASIC, PRECLINICAL, AND TRANSLATIONAL RESEARCH THAT CAN BE APPLIED DIRECTLY TO OPTIMIZING CANCER IMMUNOTHERAPY IN THE CLINIC. CLIP GRANTS PROVIDE UP TO $200,000 OVER TWO YEARS. TECHNOLOGY IMPACT AWARD: THE CRI TECHNOLOGY IMPACT AWARD PROVIDES SEED FUNDING OF UP TO $200,000 TO BE USED OVER 24 MONTHS TO ADDRESS THE GAP BETWEEN TECHNOLOGY DEVELOPMENT AND CLINICAL APPLICATION OF CANCER IMMUNOTHERAPIES. IMPACT GRANTS: CRI IMPACT GRANTS SUPPORT RESEARCH PROJECTS AND PUBLIC EDUCATION AND AWARENESS INITIATIVES WITHIN OR APPLICABLE TO THE FIELDS OF IMMUNOLOGY AND TUMOR IMMUNOLOGY FOR WHICH FUNDS HAVE BEEN SPECIFICALLY RAISED.
PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 11	THE CEO AND THE CFO WORK WITH THE AUDIT FIRM TO PREPARE THE TAX RETURNS. A DRAFT COPY IS CIRCULATED TO THE ENTIRE BOARD FOR REVIEW AND COMMENTS, AFTER WHICH IT IS SIGNED AND FILED WITH RELEVANT AUTHORITIES.
PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 12C	ALL MEMBERS OF THE BOARD AND THE ENTIRE STAFF ARE GIVEN THE CONFLICT OF INTEREST DOCUMENT. THEY ARE ASKED TO ANSWER ALL QUESTIONS AND MAKE THE NECESSARY DECLARATIONS AND THEN SIGN THE DOCUMENT ON AN ANNUAL BASIS.
PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 15	THE PROCESS FOR DETERMINING COMPENSATION OF THE CEO IS DETERMINED BY USING COMPARABLE DATA AND IS REVIEWED BY THE BOARD OF TRUSTEES CO-CHAIRMEN.
PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 19	AT LEAST THE THREE MOST RECENT YEARS OF FINANCIAL INFORMATION ARE POSTED ON CRI'S WEBSITE. THE GENERAL PUBLIC CAN ALSO REQUEST A COPY TO BE SENT TO THEM, AS WELL AS VIEW THEM AT OUR OFFICES AT 29 BROADWAY, 4TH FLOOR NEW YORK, NY 10006. Governing documents are only distributed internally to management and the Board of Trustees.
PART XI - RECONCILIATION OF NET ASSETS, LINE 9	OTHER CHANGES IN NET ASSETS OR FUND BALANCES - INCLUDE THE GAIN IN VALUE OF PERPETUAL TRUST OF $152,663, A RETURN OF GRANT FUNDS IN THE AMOUNT OF $62,274, AND EARLY GRANT TERMINATIONS IN THE AMOUNT OF $779,420.

Return Reference

Explanation

PART III - STATEMENT OF PROGRAM ACCOMPLISHMENTS, LINE 4D

CLINIC AND LABORATORY INTEGRATION PROGRAM: THE CRI CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP) SUPPORTS QUALIFIED SCIENTISTS WHO ARE WORKING TO EXPLORE CLINICALLY RELEVANT QUESTIONS AIMED AT IMPROVING THE EFFECTIVENESS OF CANCER IMMUNOTHERAPIES. THE PROGRAM FUNDS BASIC, PRECLINICAL, AND TRANSLATIONAL RESEARCH THAT CAN BE APPLIED DIRECTLY TO OPTIMIZING CANCER IMMUNOTHERAPY IN THE CLINIC. CLIP GRANTS PROVIDE UP TO $200,000 OVER TWO YEARS. TECHNOLOGY IMPACT AWARD: THE CRI TECHNOLOGY IMPACT AWARD PROVIDES SEED FUNDING OF UP TO $200,000 TO BE USED OVER 24 MONTHS TO ADDRESS THE GAP BETWEEN TECHNOLOGY DEVELOPMENT AND CLINICAL APPLICATION OF CANCER IMMUNOTHERAPIES. IMPACT GRANTS: CRI IMPACT GRANTS SUPPORT RESEARCH PROJECTS AND PUBLIC EDUCATION AND AWARENESS INITIATIVES WITHIN OR APPLICABLE TO THE FIELDS OF IMMUNOLOGY AND TUMOR IMMUNOLOGY FOR WHICH FUNDS HAVE BEEN SPECIFICALLY RAISED.

PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 11

THE CEO AND THE CFO WORK WITH THE AUDIT FIRM TO PREPARE THE TAX RETURNS. A DRAFT COPY IS CIRCULATED TO THE ENTIRE BOARD FOR REVIEW AND COMMENTS, AFTER WHICH IT IS SIGNED AND FILED WITH RELEVANT AUTHORITIES.

PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 12C

ALL MEMBERS OF THE BOARD AND THE ENTIRE STAFF ARE GIVEN THE CONFLICT OF INTEREST DOCUMENT. THEY ARE ASKED TO ANSWER ALL QUESTIONS AND MAKE THE NECESSARY DECLARATIONS AND THEN SIGN THE DOCUMENT ON AN ANNUAL BASIS.

PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 15

THE PROCESS FOR DETERMINING COMPENSATION OF THE CEO IS DETERMINED BY USING COMPARABLE DATA AND IS REVIEWED BY THE BOARD OF TRUSTEES CO-CHAIRMEN.

PART VI - GOVERNANCE, MANAGEMENT AND DISCLOSURE, LINE 19

AT LEAST THE THREE MOST RECENT YEARS OF FINANCIAL INFORMATION ARE POSTED ON CRI'S WEBSITE. THE GENERAL PUBLIC CAN ALSO REQUEST A COPY TO BE SENT TO THEM, AS WELL AS VIEW THEM AT OUR OFFICES AT 29 BROADWAY, 4TH FLOOR NEW YORK, NY 10006. Governing documents are only distributed internally to management and the Board of Trustees.

PART XI - RECONCILIATION OF NET ASSETS, LINE 9

OTHER CHANGES IN NET ASSETS OR FUND BALANCES - INCLUDE THE GAIN IN VALUE OF PERPETUAL TRUST OF $152,663, A RETURN OF GRANT FUNDS IN THE AMOUNT OF $62,274, AND EARLY GRANT TERMINATIONS IN THE AMOUNT OF $779,420.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2020

Software ID:
Software Version: